Hookipa Pharma Inc. (Nasdaq: HOOK)

https://www.hookipabiotech.com

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, selfantigens and next-generation antigens. *

	Start	2018-09-13 established before
	Group	Hookipa (Group)
	Predecessor	Hookipa Biotech AG
	Industry	Vaxwave® technology
	Industry 2	HB-101 (Hookipa)
	Person	Aldag, Jörn (Hookipa Biotech 201606– CEO before Uniqure/AMT + Evotec + MAN GHH)

	Region	New York, NY
	Country	United States (USA)
	Street	350 Fifth Avenue 72nd Floor, Suite 7240
	City	10118 New York, NY
	Tel	+43-1-890-6360
		Address record changed: 2024-01-12

Basic data	Employees	D: 101 to 500 (2023-02-28)
	Currency	USD
	Annual sales	14,249,000 (revenue, consolidated (2022) 2022-12-31)
	Profit	-64,915,000 (2022-12-31)
	Cash	117,500,000 (2023-12-31)

		* Document for »About Section«: Hookipa Pharma Inc.. (2/26/19). "Press Release: Hookipa Pharma Raises $37.4 Million (€33.2 Million) in Series D Financing". New York, NY & Vienna.

		Record changed: 2024-02-06